echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pioneer of Innovative Tumor Immune AI Drugs-Xunbaihui Biotechnology completed Series B financing, Coatue led the investment

    Pioneer of Innovative Tumor Immune AI Drugs-Xunbaihui Biotechnology completed Series B financing, Coatue led the investment

    • Last Update: 2021-10-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, October 15, 2021 /PRNewswire/ - October 14 news, Xunbaihui Biotechnology Co.


    Xunbaihui combines functional genomics and AI to develop new cancer immune antibody drugs

    The meeting of hundred veins reaches the whole body


    Relying on two core technology platforms, Xunbaihui’s first original antibody drug is aimed at a brand-new cancer immune checkpoint.


    About Coatue

    Coatue is one of the world's largest technology investment institutions, managing more than US$40 billion in assets


    About Xunbaihui

    Xunbaihui and its parent company GV20 Oncotherapy were established in 2016.


    Source: Xunbaihui

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.